CoChat

Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells

Tong, Jingshan, Wang, Peng, Tan, Shuai, Chen, Dongshi, Nikolovska-Coleska, Zaneta, Zou, Fangdong, Yu, Jian, Zhang, Lin · 2017 · Cancer Research

Published version of a preprint

Cited by 129

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The Bcl-2 family protein Mcl-1 is often degraded in cancer cells subjected to effective therapeutic treatment, and defective Mcl-1 degradation has been associated with intrinsic and acquired drug resistance. However, a causal relationship between Mcl-1 degradation and anticancer drug responses has not been directly established, especially in solid tumor cells where Mcl-1 inhibition alone is insufficient to trigger cell death. In this study, we present evidence that Mcl-1 participates directly in determining effective therapeutic responses in colon cancer cells. In this setting, Mcl-1 degradation was induced by a variety of multikinase inhibitor drugs, where it relied upon GSK3β phosphorylation and FBW7-dependent ubiquitination. Specific blockade by genetic knock-in (KI) abolished apoptotic responses and conferred resistance to kinase inhibitors. Mcl-1-KI also suppressed the antiangiogenic and anti-hypoxic effects of kinase inhibitors in the tumor microenvironment. Interestingly, these same inhibitors also induced the BH3-only Bcl-2 family protein PUMA, which is required for apoptosis. Degradation-resistant Mcl-1 bound and sequestered PUMA from other prosurvival proteins to maintain cell survival, which was abolished by small-molecule Mcl-1 inhibitors. Our findings establish a pivotal role for Mcl-1 degradation in the response of colon cancer cells to targeted therapeutics, and they provide a useful rational platform to develop Mcl-1–targeting agents that can overcome drug resistance. Cancer Res; 77(9); 2512–21. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-3242

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 40

  1. Bhola, 2016, Mitochondria-judges and executioners of cell death sentences, Mol Cell, 61, 695, 10.1016/j.molcel.2016.02.019 · DOI · Paper page
  2. Thomas, 2010, Mcl-1; the molecular regulation of protein function, FEBS Lett, 584, 2981, 10.1016/j.febslet.2010.05.061 · DOI · Paper page
  3. Perciavalle, 2013, Delving deeper: MCL-1′s contributions to normal and cancer biology, Trends Cell Biol, 23, 22, 10.1016/j.tcb.2012.08.011 · DOI · Paper page
  4. Mojsa, 2014, Mcl-1 ubiquitination: unique regulation of an essential survival protein, Cells, 3, 418, 10.3390/cells3020418 · DOI · Paper page
  5. Zhong, 2005, Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis, Cell, 121, 1085, 10.1016/j.cell.2005.06.009 · DOI · Paper page
  6. Ding, 2007, Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization, Mol Cell Biol, 27, 4006, 10.1128/MCB.00620-06 · DOI · Paper page
  7. Inuzuka, 2011, SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction, Nature, 471, 104, 10.1038/nature09732 · DOI · Paper page
  8. Wertz, 2011, Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7, Nature, 471, 110, 10.1038/nature09779 · DOI · Paper page
  9. Opferman, 2005, Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells, Science, 307, 1101, 10.1126/science.1106114 · DOI · Paper page
  10. Fernandez-Marrero, 2016, Survival control of malignant lymphocytes by anti-apoptotic MCL-1, Leukemia, 30, 2152, 10.1038/leu.2016.213 · DOI
  11. Wilhelm, 2008, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, Mol Cancer Ther, 7, 3129, 10.1158/1535-7163.MCT-08-0013 · DOI · Paper page
  12. Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 · DOI · Paper page
  13. Abou-Elkacem, 2013, Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model, Mol Cancer Ther, 12, 1322, 10.1158/1535-7163.MCT-12-1162 · DOI · Paper page
  14. Tong, 2017, FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation, Oncogene, 36, 787, 10.1038/onc.2016.247 · DOI · Paper page
  15. Yu, 2003, PUMA mediates the apoptotic response to p53 in colorectal cancer cells, Proc Natl Acad Sci U S A, 100, 1931, 10.1073/pnas.2627984100 · DOI · Paper page
  16. Abulwerdi, 2014, A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo, Mol Cancer Ther, 13, 565, 10.1158/1535-7163.MCT-12-0767 · DOI · Paper page
  17. Abulwerdi, 2014, 3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation, J Med Chem, 57, 4111, 10.1021/jm500010b · DOI
  18. Peng, 2013, Targeting Bax interaction sites reveals that only homo-oligomerization sites are essential for its activation, Cell Death Differ, 20, 744, 10.1038/cdd.2013.4 · DOI
  19. Yu, 2006, PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation, Clin Cancer Res, 12, 2928, 10.1158/1078-0432.CCR-05-2429 · DOI
  20. Ming, 2006, PUMA dissociates Bax and BCL-XL to induce apoptosis in colon cancer cells, J Biol Chem, 281, 16034, 10.1074/jbc.M513587200 · DOI · Paper page
  21. Dudgeon, 2012, Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3beta and NF-kappaB to suppress tumor cell growth, Oncogene, 31, 4848, 10.1038/onc.2011.644 · DOI
  22. Chen, 2014, Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis, Clin Cancer Res, 20, 3472, 10.1158/1078-0432.CCR-13-2944 · DOI
  23. Dudgeon, 2010, PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01, Mol Cancer Ther, 9, 2893, 10.1158/1535-7163.MCT-10-0635 · DOI
  24. Sun, 2012, The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA, PLoS One, 7, e43158, 10.1371/journal.pone.0043158 · DOI
  25. Wang, 2006, Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins, J Med Chem, 49, 6139, 10.1021/jm060460o · DOI · Paper page
  26. Billard, 2013, BH3 mimetics: status of the field and new developments, Mol Cancer Ther, 12, 1691, 10.1158/1535-7163.MCT-13-0058 · DOI · Paper page
  27. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  28. Medina, 2016, Do not let death do us part: ‘find-me’ signals in communication between dying cells and the phagocytes, Cell Death Differ, 23, 979, 10.1038/cdd.2016.13 · DOI · Paper page
  29. Ricotta, 2013, Regorafenib for metastatic colorectal cancer, Lancet, 381, 1537, 10.1016/S0140-6736(13)60976-9 · doi:10.1016/s0140-6736(13)60976-9
  30. Del Poeta, 2016, Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia, Drugs Today, 52, 249, 10.1358/dot.2016.52.4.2470954 · DOI
  31. Konopleva, 2006, Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia, Cancer Cell, 10, 375, 10.1016/j.ccr.2006.10.006 · DOI · Paper page
  32. Tahir, 2007, Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737, Cancer Res, 67, 1176, 10.1158/0008-5472.CAN-06-2203 · DOI · Paper page
  33. van Delft, 2006, The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell, 10, 389, 10.1016/j.ccr.2006.08.027 · DOI · Paper page
  34. Day, 2008, Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1, J Mol Biol, 380, 958, 10.1016/j.jmb.2008.05.071 · DOI · Paper page
  35. Youle, 2008, The BCL-2 protein family: opposing activities that mediate cell death, Nat Rev Mol Cell Biol, 9, 47, 10.1038/nrm2308 · DOI · Paper page
  36. Friberg, 2013, Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design, J Med Chem, 56, 15, 10.1021/jm301448p · DOI · Paper page
  37. Pelz, 2016, Discovery of 2-Indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods, J Med Chem, 59, 2054, 10.1021/acs.jmedchem.5b01660 · DOI · Paper page
  38. Cohen, 2012, A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival, Chem Biol, 19, 1175, 10.1016/j.chembiol.2012.07.018 · DOI · Paper page
  39. Nguyen, 2007, Small molecule obatoclax (GX15–070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis, Proc Natl Acad Sci U S A, 104, 19512, 10.1073/pnas.0709443104 · DOI · Paper page
  40. Wei, 2011, An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins, Front Oncol, 1, 28, 10.3389/fonc.2011.00028 · DOI

Cited by

See all 129

Metadata

Authors
Tong, J., Wang, P., Tan, S., Chen, D., Nikolovska-Coleska, Z., Zou, F., Yu, J., & Zhang, L.
Venue
Cancer Research
Published
2017-04-30
Volume
77
Issue
9
Pages
2512-2521
ISSN
  • 0008-5472
  • 1538-7445
Cited by
129
References
9
Language
en
Funders
  • NIH (R01CA106348, R01CA172136, and R01CA203028, U01DK085570 and U19AI068021, R01CA149442)
  • National Natural Science Foundation of China (81672942)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-3242
The paper
Tong, J., Wang, P., Tan, S., Chen, D., Nikolovska-Coleska, Z., Zou, F., Yu, J., & Zhang, L. (2017). Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-3242

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.